Mrs. Eileen B Herbeck is a pharmacist who is specialized in Oncology in Longview, Texas. Patients can reach her at 1300 N 4th St, Longview or contact her on 903-234-7060. Active license number of Mrs. Eileen B Herbeck is 23409 for Oncology in Texas. Mrs. Eileen B Herbeck is a licensed pharmacist who has demonstrated specialized knowledge and skill in developing, recommending, implementing, monitoring, and modifying pharmacotherapeutic plans to optimize outcomes in patients with malignant diseases.
Complete Profile:
Mrs. Eileen B Herbeck speciality, credentials, practice address, contact phone number and fax are as below. Patients can call on the below given phone number for enquiries.
Name:
Mrs. Eileen B Herbeck
Specialization:
Oncology
Credentials:
R.PH.
Gender:
Female
Location:
1300 N 4th St, Longview, Texas, 75601-4717
Phone:
903-234-7060
Fax:
903-753-2249
Professional Identification Codes:
NPI number stands for National Provider Identifier which is a unique 10-digit identification number issued to health care providers in the United States by the Centers for Medicare and Medicaid Services (CMS).
NPI details of Mrs. Eileen B Herbeck are as mentioned below.
NPI Number:
1841361318
NPI Enumeration Date:
13 Nov, 2006
NPI Last Update On:
08 Jul, 2007
Medical Licenses:
Pharmacists can have one or more medical licenses for different specialities in the same state or different states. Related medical licenses for Mrs. Eileen B Herbeck are as mentioned below.
Specialization
License Number
State
Status
Oncology
23409
Texas
Primary
Business Mailing Address:
Business mailing address can be used for mailing purpose only, for visiting purpose patients need to refer above mentioned address.
Address:
1300 N 4th St, Longview, Texas
Zip:
75601-4717
Phone Number:
903-234-7060
Fax Number:
903-753-2249
Patients can reach Mrs. Eileen B Herbeck at 1300 N 4th St, Longview, Texas or can call on phone at 903-234-7060.
Comments/ Reviews:
*Data of this site is collected from Medicare & Medicaid Services (CMS) and NPPES. Last updated on 13 May, 2024.